Mogamulizumab in the treatment of cutaneous T cell lymphoma

References

• Zinzani P, Bonthapally V, Huebner D, et al. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:228–240.
   PubMed Web of Science ®Google Scholar
• Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–5073.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe E, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Jahan-Tigh RR, Huen AO, Lee GL, et al. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer. 2013;119(4):825–831.
   PubMed Web of Science ®Google Scholar
• Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89(1):32–40.
   PubMed Web of Science ®Google Scholar
• Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159(1):105–112.
   PubMed Web of Science ®Google Scholar
• Tokura Y, Yagi H, Ohshima A, et al. Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial super antigens. Br J Dermatol. 1995;133(1):6–12.
   PubMed Web of Science ®Google Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–866.
   PubMedGoogle Scholar
• Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–5060.
   PubMed Web of Science ®Google Scholar
• Talpur R, Sui D, Gangar P, et al. Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016;16(1):49–56.
   PubMed Web of Science ®Google Scholar
• Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome. Blood. 2016;127(25):3142–3153.
   PubMed Web of Science ®Google Scholar
• Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology Am Soc Hematol Educ Program. 2015;2015:529–544.
   PubMedGoogle Scholar
• Duvic M, Donato M, Dabaja B, et al. Total skin electron bean and non-myeloablative allogenic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28(14):2365–2372.
   PubMed Web of Science ®Google Scholar
• Chung CG, Poligone B. Cutaneous T cell lymphoma: an update on pathogenesis and systemic therapy. Curr Hematol Malig Rep. 2015;10(4):468–476.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Mogamulizumab: 2 birds, 1 stone. Blood. 2015;125(12):1847–1848.
   PubMed Web of Science ®Google Scholar
• Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174.
   PubMed Web of Science ®Google Scholar
• Ni X, Langridge T, Duvic M. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology. 2015;4(7):e1011524. DOI:10.1080/2162402X.2015.1011524
   PubMed Web of Science ®Google Scholar
• Sugaya M, Morimura S, Suga H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol. 2015;42(6):613–615.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–3473.
   PubMed Web of Science ®Google Scholar
• Yano H, Ishida T, Inagaki A, et al. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2007;13(21):6494–6500.
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Dufucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–1531.
   PubMed Web of Science ®Google Scholar
• Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulator T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2015;21(2):274–285.
   PubMed Web of Science ®Google Scholar
• Duvic M, Pinter-Brown L, Foss F, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma Blood. 2015;125(12):1883–1889.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–1163.
   PubMed Web of Science ®Google Scholar
• Subramaniam J, Whiteside G, Mckeage K, et al. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293–1298.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–1598.
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–842.
   PubMed Web of Science ®Google Scholar
• Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–682.
   PubMed Web of Science ®Google Scholar
• Ureshino H, Shindo T, Nishikawa H, et al. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016. DOI:10.1158/2326-6066.CIR-15-0303
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Murahashi M, Katsuya H, et al. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. Int J Hematol. 2015;102(4):493–497.
   PubMed Web of Science ®Google Scholar
• Morichika K, Tomoyose T, Hanashiro T, et al. Recurrence of psoriasis vulgaris accompanied by treatment with C-C chemokine receptor type 4 (CCR4) antibody (Mogamulizumab) therapies in a patient with adult T cell leukemia/lymphoma: insight into autoinflammatory diseases. Intern Med. 2016;55(10):1345–1349.
   PubMed Web of Science ®Google Scholar
• Mogamulizumab. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2016. https://clinicaltrials.gov/ct2/results?term=mogamulizumab
   Google Scholar